According to filings with the U.S. Securities and Exchange Commission, Elegen is raising up to $35,982,969.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Matthew Hill played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elegen
We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanitys greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

To learn more about Elegen, visit http://www.elegenbio.com/

Contact:
Matthew Hill, Chief Executive Officer
650-255-1712
https://www.linkedin.com/in/mhillphd/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.